Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
RTK protein kinase inhibitor AB 1010 , 5 mg  

RTK protein kinase inhibitor AB 1010 , 5 mg

4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide methanesulfonate

Synonyms: Masitinib mesylate
AB 1010 is a potent oral tyrosine kinase inhibitor, targeting c-KIT, PDGFR and FGFR3

More details

PKI-AB1010-005

Availability: within 3 days

110,50 €

Background: AB 1010 is a potent oral tyrosine kinase inhibitor, targeting c-KIT and PDGFR alpha / PDGFR beta with IC50 of 200 nM and 540 nM/800 nM and FGFR3; oncology drug under clinical trial.

Chemical formula: C28H30N6OS.CH4O3S
Molecular weight: 594.75 g/mol
Purity: 99 %
Appearance: Yellow solid
Solubility: Soluble in water and DMSO
CAS Number: 1048007-93-7

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

P Dubreuil et al. Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. Plos ONE 2009, 4(9), e7258.
 
BN Bui et al. Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study. J. Clin. Onco. 2007, 25(18S), 10025.
 
G Giamas et al. Protein kinases as targets for cancer treatment. Pharmacogenomics. 2007, 8(8), 1005-1016.
 
KA Hahn et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22(6), 1301-1309.